CN1325403A - 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 - Google Patents
胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 Download PDFInfo
- Publication number
- CN1325403A CN1325403A CN99812751A CN99812751A CN1325403A CN 1325403 A CN1325403 A CN 1325403A CN 99812751 A CN99812751 A CN 99812751A CN 99812751 A CN99812751 A CN 99812751A CN 1325403 A CN1325403 A CN 1325403A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hydrogen
- independently
- phenyl
- another
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 title description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims description 99
- 229910052739 hydrogen Inorganic materials 0.000 claims description 99
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 56
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 47
- -1 methoxyl group Chemical group 0.000 claims description 44
- 229910052801 chlorine Inorganic materials 0.000 claims description 42
- 229910052731 fluorine Inorganic materials 0.000 claims description 42
- 150000002431 hydrogen Chemical class 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 9
- 230000035790 physiological processes and functions Effects 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052728 basic metal Inorganic materials 0.000 claims description 6
- 150000003818 basic metals Chemical class 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 abstract 1
- 208000001130 gallstones Diseases 0.000 abstract 1
- 150000002357 guanidines Chemical class 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 18
- 239000002585 base Substances 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 150000001555 benzenes Chemical class 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 210000000941 bile Anatomy 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 238000010265 fast atom bombardment Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229940005605 valeric acid Drugs 0.000 description 10
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 239000004380 Cholic acid Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 235000019416 cholic acid Nutrition 0.000 description 8
- 229960002471 cholic acid Drugs 0.000 description 8
- 238000013016 damping Methods 0.000 description 8
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 8
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 2-(6-amino-1h-indol-3-yl)acetonitrile Chemical compound NC1=CC=C2C(CC#N)=CNC2=C1 ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 0.000 description 4
- DLYVTEULDNMQAR-SRNOMOOLSA-N Cholic Acid Methyl Ester Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCC(=O)OC)[C@@]2(C)[C@@H](O)C1 DLYVTEULDNMQAR-SRNOMOOLSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUXRZQZCNOHHDO-UHFFFAOYSA-N 2-phosphonopropanoic acid Chemical compound OC(=O)C(C)P(O)(O)=O GUXRZQZCNOHHDO-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004348 Glyceryl diacetate Substances 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical group C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- VXTQKJXIZHSXBY-UHFFFAOYSA-N butan-2-yl 2-methylprop-2-enoate Chemical compound CCC(C)OC(=O)C(C)=C VXTQKJXIZHSXBY-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000019443 glyceryl diacetate Nutrition 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940054441 o-phthalaldehyde Drugs 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical class N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710097665 Leucine aminopeptidase 1 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical class OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710082688 Probable leucine aminopeptidase 1 Proteins 0.000 description 1
- 108091006649 SLC9A3 Proteins 0.000 description 1
- 102000046061 Sodium-Hydrogen Exchanger 3 Human genes 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 102100022147 Torsin-1A-interacting protein 1 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical group 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical class ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-BFGUONQLSA-N phthalic acid Chemical compound O[13C](=O)C1=CC=CC=C1[13C](O)=O XNGIFLGASWRNHJ-BFGUONQLSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及取代的苯基链烯酰基胍及其可药用盐和生理功能衍生物。本发明公开了式(Ⅰ)化合物,其中各基团的定义同说明书所述。本发明还公开了式(Ⅰ)化合物的生理可接受盐、生理功能衍生物及其制备方法。本发明化合物适于例如用作预防或治疗胆结石的药物。
Description
本发明涉及取代的苯基链烯酰基胍及其可药用盐和生理功能衍生物。
尽管有多种因素,但是胆结石的形成基本上是由胆汁的组成、特别是胆固醇、磷脂和胆汁盐的浓度和比例决定的。形成胆固醇胆结石的先决条件是存在胆固醇过饱和的胆汁(Ref.Carey,M.C.和Small,D.M.(1978),胆汁中胆固醇溶解性的物理化学。在人体中胆结石形成与溶解之间的关系,J.Clin.Invest.61:998-1026)。
到目前为止,胆结石主要是通过手术除去,因此在医疗上对于胆结石溶解和预防胆结石形成有很大需要。
本发明是基于下述目的:即获得能通过阻止胆固醇在胆汁中过饱和、或者通过延迟从过饱和胆汁形成胆固醇结晶来防止胆结石形成的化合物。
因此,本发明涉及式Ⅰ化合物及其可药用盐和生理功能衍生物,其中T1和T2彼此独立地为或氢,其中T1和T2不能同时为氢;z是R(A)、R(B)、R(C)、R(D)彼此独立地为氢、F、Cl、Br、I、CN、OH、NH2、-(C1-C8)-烷基、-O-(C1-C8)-烷基(其中所述烷基可被F取代一次或多次)(C3-G8)-环烷基、苯基、苄基、NHR(7)、NR(7)R(8)、O-(C3-C6)-链烯基、O-(C3-C8)-环烷基、O-苯基、O-苄基(其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次);R(7)、R(8)彼此独立地为氢、-(C1-C8)-烷基(其中所述烷基可被F取代一次或多次),(C3-C8)-环烷基、(C3-C6)-链烯基、(C3-C8)-环烷基、苯基、苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;或者R(7)、R(8)一起形成具有4或5个亚甲基的链,其中的一个CH2基团可被氧、硫、NH、N-CH3或N-苄基替代;R(9)、R(10)彼此独立地为氢、(C1-C4)-烷基、(C1-C4)-全氟烷基;x是0、1或2;y是0、1或2;R(E)、R(F)彼此独立地为氢、F、Cl、Br、I、CN、(C1-C8)-烷基、O-(C1-C8)-烷基(其中所述烷基可被F取代一次或多次)、(C3-C8)-环烷基、O-(C3-C6)-链烯基、O-(C3-C8)-环烷基、O-苯基、O-苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;R(1)、R(2)、R(3)彼此独立地为氢、F、Cl、Br、I、CN、-(C1-C8)-烷基、-O-(C1-C8)-烷基(其中所述烷基可被F取代一次或多次)、-(C=O)-N=C(NH2)2、-(SO0-2)-(C1-C8)-烷基、-(SO2)-NR(7)R(8)、-O-(C0-C8)-亚烷基苯基、-(C0-C8)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、-(C0-C8)-亚烷基-NR(9)R(10)取代最高达3次;L是-O-、-NR(47)-、-(C1-C8)-亚烷基-、-(C1-C8)-亚链烯基-、-(C1-C8)-亚炔基-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-O-CO-(CH2)n-O-、-SO2-NR(48)-(CH2)n-O-、-NR(48)-CO-CH2-CH2-CO-NR(48)-(CH2)n-O-、-NR(48)-CO-CH=CH-CO-NR(48)-(CH2)n-O-、-NR(48)-SO2-(CH2)n-O-;R(47)是氢、(C1-C8)-烷基、R(48)-CO-、苯基、苄基;R(48)是氢、(C1-C8)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;n是1-8;R(40)-R(45)彼此独立地为氢、-OR(50)、-SR(50)、NHR(50)、-NR(50)2、-O-(CO)-R(50)、-S-(CO)-R(50)、-NH-(CO)-R(50)、-O-PO-(OR(50))-OR(50)、-O-(SO2)-OR(50)、-R(50)、L上的键;或者每种情况下的R(40)与R(41)、R(42)与R(43)、R(44)与R(45)-起形成羰基的氧;其中R(40)-R(45)当中总是恰好有一个基团具有L上的键的意义;K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-NH-CH2-COOH、-N(CH3)CH2CO2H、-HN-CH(R46)CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子;R(46)是氢、C1-C4-烷基、苄基、-CH2-OH、H3CSCH2CH2-、HO2CCH2-、HO2CCH2CH2-;R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次。
定义如下的式Ⅰ化合物及其可药用盐和生理功能衍生物是优选的,其中T1和T2彼此独立地为或氢,其中T1和T2不能同时为氢;L-z是R(E)是氢、F、Cl、CN、(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次,或者R(E)为(C3-C6)-环烷基、(C3-C8)-链烯基、O-(C3-C6)-环烷基、O-苯基、O-苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;R(9)、R(10)彼此独立地为氢、CH3、CF3;R(1)、R(2)、R(3)彼此独立地为氢、F、Cl、CN、-SO2-(C1-C4)-烷基、-SO2-N((C1-C4)-烷基)2、-SO2-NH(C1-C4)-烷基、-SO2-NH2、-SO2-(C1-C4)-烷基、-(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为-O-(C0-C4)-亚烷基苯基、-(C0-C4)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;L是-O-、-NR(47)-、-(C1-C4)-亚烷基-、-(C1-C4)-亚链烯基-、-(C1-C4)-亚炔基-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-SO2-NR(48)-(CH2)n-O-;R(47)是氢、(C1-C4)-烷基、R(48)-CO-、苯基、苄基;R(48)是氢、(C1-C4)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;n是1-4;R(41)、R(42)、R(45)彼此独立地为氢、-OR(50)、NHR(50)、-NR(50)2、-O-(CO)-R(50)、-NH-(CO)-R(50);R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-NH-CH2-COOH、-N(CH3)CH2CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子。
定义如下的式Ⅰ化合物及其可药用盐是特别优选的,其中T1和T2彼此独立地为或氢,其中T1和T2不能同时为氢;L-z是R(E)是氢、F、Cl、CN、(C1-C4)-烷基、(C1-C4)-烷基、-O(C1-C4)-烷基、CF3、-OCF3;R(1)、R(2)彼此独立地为氢、F、Cl、CN、-SO2-CH3、-SO2NH2、-(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代-次或多次,或者彼此独立地为-O-(C0-C4)-亚烷基苯基、-(C0-C4)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;R(3)是氢;L是-O-、-NR(47)-、-CH2-CH2-、-CH=CH-、-(C≡C)-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-SO2-NR(48)-(CH2)n-O-;R(47)是氢、(C1-C4)-烷基、R(48)-CO-、苯基、苄基;R(48)是氢、(C1-C4)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;n是1-4;R(41)是氢、-OH;K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-NH-CH2-COOH、-N(CH3)CH2CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子;R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次。
非常特别优选的式Ⅰ化合物是式Ⅰa化合物及其可药用盐,其中T1和T2彼此独立地为或氢,其中T1和T2不能同时为氢;L-z是L是-C≡C-、-NH-CH2-CH2-O-;R(E)是氢、(C1-C4)-烷基;R(1)、R(2)彼此独立地为氢、F、Cl、CN、-SO2-CH3、-(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次。
上式中的“*”表示T1或T2与式Ⅰ苯环的连接点。
如果式Ⅰ化合物含有一个或多个不对称中心,则它们可具有S或R构型。本发明化合物可作为光学异构体、非对映异构体、外消旋体或它们的混合物存在。
式Ⅰ化合物的双键几何构型可以为E或Z型。式Ⅰ化合物可以作为双键异构体以混合物形式存在。
用语“其中所述烷基可以被F取代一次或多次”还包括全氟化烷基。
所指定的烷基可以是直链或支链烷基。
可药用盐由于具有相当高的水溶性而比原始化合物或基本化合物更适于医药应用。这些盐必须具有可药用阴离子或阳离子。本发明化合物合适的可药用酸加成盐是无机酸盐,例如与盐酸、氢溴酸、磷酸、偏磷酸、硝酸、磺酸和硫酸形成的盐,也可以是有机酸盐,例如与乙酸、苯磺酸、苯甲酸、柠檬酸、乙磺酸、富马酸、葡萄糖酸、乙醇酸、羟乙磺酸、乳酸、乳糖酸、马来酸、苹果酸、甲磺酸、琥珀酸、对甲苯磺酸、酒石酸和三氟乙酸形成的盐。氯盐特别优选用于医药应用。合适的可药用基本盐是铵盐、碱金属盐(例如钠盐和钾盐)和碱土金属盐(例如镁盐和钙盐)。
与非可药用阴离子形成的盐同样包括在本发明范围内,因为它们可用作制备或纯化可药用盐的中间体,和/或用于非治疗应用,例如体外应用。
本文所用术语“生理功能衍生物”是指本发明式Ⅰ化合物的任何生理可耐受衍生物,例如施用给哺乳动物例如人后能(直接或间接)形成式Ⅰ化合物或其活性代谢物的酯。
生理功能衍生物还包括本发明化合物的前体药物。这种前体药物在体内能代谢成本发明化合物。这些前体药物自身可以有活性或无活性。
本发明化合物还可以以各种多晶型物形式、例如非晶形和结晶多晶型物形式存在。本发明化合物的所有多晶型物形式都包括在本发明范围内,并且是本发明的另一个方面。
在下文中,所提及的所有“式(Ⅰ)化合物”都涉及上述式(Ⅰ)化合物、其盐、溶剂化物和如本文所述的生理功能衍生物。
为了达到所需生物作用而需要的式(Ⅰ)化合物的量取决于很多因素,例如所选的具体化合物、预期应用、给药方式和患者的临床症状。
式(Ⅰ)化合物的日剂量通常为0.1mg-100mg(一般是0.1mg-50mg)/天/千克体重,例如0.1-10mg/kg/天。片剂或胶囊可包含例如0.01-100mg、一般是0.02-50mg。对于可药用盐,上述重量数据涉及衍生自该盐的氨基丙醇离子的重量。为了预防或治疗上述病症,式(Ⅰ)化合物可作为化合物本身使用,但是优选将其与可药用赋形剂制成药物组合物。赋形剂在性质上必须是可药用的,也就是说其与组合物的其它组分是相配伍的,并且对患者的健康无害。赋形剂可以是固体或液体或两者,并且优选与化合物一起配制成单位剂型,例如含有0.05%-95%重量的活性化合物的片剂。还可以存在其它药物活性物质,包括其它式(Ⅰ)化合物。本发明药物组合物可依据一种已知的制药方法制得,该已知的制药方法基本上包括将活性组分与可药用赋形剂和/或辅料混合。
本发明药物组合物是适于口服和经口(例如舌下)给药的药物组合物,但是对于每一具体情况,最合适的给药方式取决于欲治疗病症的性质和严重程度、以及每种情况下所用的式(Ⅰ)化合物的类型。包衣制剂和包衣延迟释放制剂也包括在本发明范围内。耐酸和肠溶制剂是优选的。合适的肠溶包衣包括邻苯二甲酸乙酸纤维素、聚邻苯二甲酸乙酸乙烯酯、邻苯二甲酸羟丙基甲基纤维素和甲基丙烯酸以及甲基丙烯酸甲酯的阴离子聚合物。
用于口服给药的合适的药物化合物可存在于独立的单元中,例如分别含有一定量式(Ⅰ)化合物的胶囊、扁囊剂、锭剂或片剂,其中的式(Ⅰ)化合物作为粉剂或粒剂,在水或非水液体中的溶液或悬浮液,或水包油或油包水型乳液。如上所述,这些组合物可通过任何合适的制药方法制得,包括将活性化合物与赋形剂(可由一种或多种附加组分组成)接触的步骤。本发明组合物一般是通过将活性化合物与液体和/或细碎的固体赋形剂均匀地混合、然后如果需要的话将所得产物定形而制得的。因此,片剂例如可通过将化合物(适当时,与一种或多种其它组分)的粉末或颗粒压制或定形而制得。压制片可通过将自由流动形式例如粉末或颗粒形式(适当时与粘合剂、润滑剂、惰性稀释剂和/或一种(多种)表面活性/分散剂混合)的化合物在合适的机器中制片而制得。定形片剂可通过将用惰性液体稀释剂润湿的粉状化合物在合适的机器中定形而制得。
适于经口(舌下)给药的药物组合物包括含有式(Ⅰ)化合物和调味剂(通常是蔗糖)和阿拉伯胶或黄蓍胶的锭剂,和在惰性基质例如明胶和甘油或蔗糖和阿拉伯胶中含有式(Ⅰ)化合物的软锭剂。
本发明还涉及制备式(Ⅰ)化合物的方法,包括将式Ⅱ化合物与A-L-z化合物以本领域技术人员已知的方式反应,以除去GA和获得式Ⅰ化合物,其中T1、T2、R(1)、R(2)和R(3)具有上述含义,并且G是可被L-z替代的官能团。
式Ⅲ乙炔胆汁酸衍生物可由合适的胆汁酸酮制得。对于此,按照与已知方法(US5641767)类似的方式,将炔锂加到酮基胆汁酸中。
式Ⅰ化合物及其可药用盐和生理功能衍生物的特征是,对胆汁组成有有利影响,并通过阻止胆固醇在胆汁中过饱和、或者通过延迟从过饱和胆汁形成胆固醇结晶来防止胆结石形成。本发明化合物可独自使用,或者与降脂活性化合物联合使用。本发明化合物特别适用于预防和治疗胆结石。
本发明的式(Ⅰ)化合物进入肝胆管系统并因此作用于这些组织。因此通过抑制胆囊上皮的亚型3顶端NHE反向转移而抑制了从胆囊吸收水,导致稀胆汁。
通过测定钠/质子交换剂亚型3的抑制作用,进行本发明化合物的生物测试。1.测试描述
为了确定抑制人NHE-3蛋白(在LAP1细胞系中表达)的IC50值,测定酸化后细胞内pH(pHi)的恢复,这种恢复即使在不含碳酸氢盐的条件下也会在功能性NHE中发生。因此,使用pH-敏感性荧光染料BCECF(Calbiochem,使用前体BCECF-AM)测定该pHi。首先向细胞中加入BCECF。用比例荧光分光计(Photon TechnologyInternational,South Brunswick,N.J.,USA)在505和440nm的激发波长和535nm的发射波长测定BCECF荧光,并通过校正曲线转化成pHi。在BCECF加样期间已经将细胞在NH4Cl缓冲液(pH7.4)中培养(NH4Cl缓冲液:115mM NaCl,20mM NH4Cl,5mM KCl,1mMCaCl2,1mM MgSO4,20mM Hepes,5mM葡萄糖,1mg/ml BSA;用1M NaOH稳定pH7.4)。通过将975μl不含NH4Cl的缓冲液加到25μl等分试样的在NH4Cl缓冲液中培养的细胞中来诱导细胞内酸化。然后记录3分钟pH恢复的速率。为了计算测试物的抑制能力,首先在发生了完全的pH恢复或根本没有发生pH恢复的缓冲液中研究细胞。为了达到(100%),将细胞在含有Na+的缓冲液(133.8mM NaCl,4.7mMKCl,1.25mM CaCl2,1.25mM MgCl2,0.97mM Na2HPO4,0.23mMNaH2PO4,5mM Hepes,5mM葡萄糖;用1M NaOH稳定pH7.0)中培养。为了测定0%值,将细胞在不含Na+的缓冲液(133.8mM氯化胆碱,4.7mM KCl,1.25mM CaCl2,1.25mM MgCl2,0.97mM K2HPO4,0.23mM KH2PO4,5mM Hepes,5mM葡萄糖;用1M NaOH稳定pH7.0)中培养。在含Na+的缓冲液中制备待测试物。在待测试物各测试浓度的细胞内pH恢复以%最大恢复表示。通过程序SigmaPlot(3.0版,Jandel Scientific,USA)由pH恢复的百分比值计算相应测试物的IC50值。结果:
实施例1 IC50=1.7μM/l
下述实施例是为了更详细地举例说明本发明,而不是将本发明限制到在这些实施例中描述的产物和实施方案上。缩写:MeOH 甲醇LAH 氢化铝锂DMF N,N一二甲基甲酰胺EI 电子碰撞CI 化学电离RT 室温EA 乙酸乙酯(EtOAc)mp 熔点HEP 正庚烷DME 甲氧基乙烷ES 电子喷雾FAB 快速原子轰击CH2Cl2 二氯甲烷THF 氢呋喃eq. 当量
用于将芳基卤与取代的末端炔烃偶合的一般方法:
将芳基卤(1eq)与辅助碱(4eq)例如三乙胺和Pd催化剂例如二(三苯基膦基)二氯化钯(3mol%)一起置于DMF中。用0.5-3小时缓慢地加入乙炔衍生物,如果需要的话,再加入上述量的催化剂。在该过程中,反应温度可能超过室温并达到大约100℃;通常是60℃。通过加入乙酸乙酯可以沉淀出粗产物并过滤。然后通过加入在丙酮中的酸来形成盐。
实施例1:4-{3β-[3,4-二(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊烷并[a]菲-17-基}戊酸二乙酸盐,淡黄色固体,熔点250℃(分解),MS:M++H(FAB)=880。
制备中间体1和2:中间体1:3β-乙炔基胆酸合成路线:a)3,7,12-三乙酰基胆酸甲酯
将90g胆酸甲酯和3.0g二甲基氨基吡啶溶于500ml吡啶,用500ml乙酸酐处理该溶液,并在室温搅拌过夜。将该溶液倒入冰水中,并用乙酸乙酯提取(3×)。干燥(MgSO4),并将有机相蒸发,获得了92g 3,7,12-三乙酰基胆酸甲酯,MS:M++Li(FAB)=555。b)7,12-二乙酰基胆酸甲酯
在5℃将150ml乙酸酐缓慢地滴加到1.5升甲醇中。15分钟后,加入92g 3,7,12-三乙酰基胆酸甲酯,将该混合物在室温搅拌1小时。将其倒入冰水中,并用乙酸乙酯提取(3×)。将有机相用1N碳酸钠溶液洗涤,用MgSO4干燥并蒸发,获得了85g粗产物,MS:M++Li(FAB)=513。c)3-酮基-7,12-二乙酰基胆酸甲酯
将85g(168mmol)7,12-二乙酰基胆酸甲酯、183.7g氯铬酸吡啶鎓(pyridinium chlorochromate)和175g分子筛在2.5升二氯甲烷中于室温搅拌2小时。将该混合物倒入7升乙醚中,并滤除固体。将溶剂蒸发,把残余物溶于乙酸乙酯中。用Florisil柱进行色谱纯化后,获得了59.6g产物,MS:M++Li(FAB)=511。d)3β-乙炔基-7,12-二乙酰基胆酸甲酯
在-55℃、氩气氛下,向750ml无水四氢呋喃中通25分钟乙炔。向该溶液中滴加145ml 15%正丁基锂的己烷溶液,搅拌10分钟。然后加入45g(89mmol)3-酮基-7,12-二乙酰基胆酸甲酯,并在-40℃搅拌混合物1.5小时。为了进行后处理,加入500ml饱和氯化铵水溶液,用乙酸乙酯提取该混合物(3×),用硫酸镁将有机相干燥并蒸发。通过硅胶色谱法(正庚烷/乙酸乙酯1∶1)纯化该残余物,获得了35.3g产物,MS:M++Li(FAB)=537。e)3β-乙炔基胆酸
将35.2g(66mmol)d)的产物溶于1升甲醇中,用300ml 2N氢氧化钠溶液处理,并加热回流25小时。将溶剂蒸发,把残余物溶于水中,用2N盐酸将该溶液酸化至pH2。滤出沉淀,用水洗涤直至呈中性。将残余物干燥,获得了14.6g产物,MS:M++Li(FAB)=439。中间体2:1,2-二[3-(E-2-甲基丙烯酸胍)]-4-溴苯二盐酸盐合成路线:a)依据标准方法(例如用LAH还原)由4-溴邻苯二甲酸二甲酯制得了4-溴-1,2-邻苯二甲醇,为无色油状物;MS(Cl):M++H=217。b)通过例如在标准条件下进行Swern氧化由2a)制得了4-溴-1,2-邻苯二甲醛,为无定形固体;MS(Cl):M++H=213。c)通过用1当量正丁基锂将1当量2-膦酰基丙酸三乙酯在己烷中于0℃去质子化,然后在室温与0.5当量4-溴-1,2-邻苯二甲醛2b)反应,制得了4-溴-1,2-二[3-(E-2-甲基丙烯酸乙酯)]苯。该二醛完全反应后,用水处理该混合物,并通过与甲苯一起振摇来提取3次。用硫酸镁将合并的有机相干燥后,将溶剂真空除去,通过硅胶色谱法分离残余的粗产物,用EA/HEP混合物洗脱,为无色油状物;MS(Cl):M++H=381。d)通过依据标准方法水解(在甲醇中的氢氧化钠)由2c)制得了4-溴-1,2-二[3-(E-2-甲基丙烯酸)]苯,为无色无定形固体;MS(ES):M++H=325。e)依据一般方法,由2d)制得了1,2-二[3-(E-2-甲基丙烯酸胍)]-4-溴苯二盐酸盐,无色固体;熔点240℃;MS(FAB):M++H=407。f)依据一般方法利用Pd(O)将2e)和3β-乙炔基胆酸在βMF中于60℃偶合2小时,制得了4-{3β-[3,4-二(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸二乙酸盐。实施例2:4-{3β-[3,4-二(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸苄酯,淡黄色固体,熔点155℃,MS:M++H(ES)=849。
用3β-乙炔基胆酸苄酯按照类似于实施例1的方法进行合成。
淡黄色固体,熔点189℃,MS:M++H(FAB)=710。
使用4-溴肉桂酸胍和3β-乙炔基胆酸苄酯依据一般方法进行合成。
实施例4:4-{3β-[4-(3-胍基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸甲酯,淡黄色固体,熔点60℃,MS:M++H(FAB)=718。
通过将4-溴肉桂酸胍和3β-乙炔基胆酸苄酯反应依据与一般方法类似的方式进行合成。
实施例5:(4-{3β-[3,4-二(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基}戊酰基氨基)乙酸。a)[4-(3β-乙炔基-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基)戊酰基氨基]乙酸甲酯
将530mg 3β-乙炔基胆酸(中间体1e)与510μl三乙胺溶于30ml THF中,在0℃滴加175μl氯甲酸乙酯。将该混合物在0℃搅拌15分钟,然后滴加340mg甘氨酸甲酯盐酸盐在10ml DMF中的溶液,将该混合物在室温搅拌4小时。将该混合物用200ml EA稀释,并用5%硫酸氢钠水溶液洗涤2次(每次50ml)。用硫酸镁干燥,将溶剂真空除去如残余物溶于100ml EA中,用饱和碳酸钠水溶液洗涤3次(每次50ml)。用硫酸镁干燥,将溶剂真空除去。通过硅胶色谱法纯化,用EA/MeOH 10∶1洗脱,然后再用EA洗脱,获得了280mg无色泡沫状物。Rf(EA)=0.37 MS(FAB):518(M+H)+。b)[4-(3β-乙炔基-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基)戊酰基氨基]乙酸
将270mg[4-(3β-乙炔基-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基)戊酰基氨基]乙酸甲酯和630μl 1N氢氧化钠水溶液溶于5ml乙醇中,并在室温放置16小时。将溶剂真空除去,用50ml饱和磷酸二氢钠水溶液将该残余物溶解,将该混合物用EA提取3次(每次50ml)。用硫酸镁干燥,将溶剂真空除去。获得了230mg无定形固体。Rf(丙酮/水10∶1)=0.25 MS(FAB):502(M+2Li)+。c)(4-{3β-[3,4-二(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基}戊酰基氨基)乙酸
依据一般方法,使用Pd(O)将230mg[4-(3β-乙炔基-3α,7α,12α-三羟基-10β,13β-二甲基十六氢环戊二烯并[a]菲-17-基)戊酰基氨基]乙酸与183mg N-{3-[4-溴-2-(3-胍基-2-甲基-3-氧代丙烯基)苯基]-2-甲基丙烯酰基}胍在60℃进行偶合反应3小时。使用C18 LiChrosorb通过制备HPLC纯化,用乙腈/水2∶4+0.1%乙酸+0.1%乙酸铵洗脱,获得了70mg无定形固体。Rf(正丁醇/冰醋酸/水3∶1∶1)=0.33 MS(ES):816(M+H)+。
实施例6:4-{3-[2-氟-4-(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3,7,12-三羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸a)3-(4-溴-3-氟苯基)-2-甲基丙烯酸丁酯
将2g1-溴-2-氟-4-碘苯与1.1ml二异丙基乙胺溶于20ml二甲基乙酰胺(无水)中,向该溶液中通5分钟缓和的氩气流。然后加入1.4ml丙烯酸丁酯和10mg 2,6-二叔丁基-4-甲基苯酚,并将该混合物加热至100℃。最后,利用氩气流将另外的4ml二甲基乙酰胺脱气,将80mg反式二(□-乙酸离子)二[邻(二邻甲苯基膦基)苄基]二钯(Tetrahedron Lett.1996,37(36),6535-6538)悬浮在其中。将该悬浮液加到其余反应物的混合物中,并在140℃搅拌90分钟。然后用200ml EA将该混合物稀释,用水洗涤2次(每次100ml),然后用100ml饱和氯化钠水溶液洗涤1次。用硫酸镁干燥,将溶剂真空除去。通过硅胶色谱法纯化,获得了230mg无色油状物。Rf(EA/HEP)=0.27 MS(DCl):315(M+H)+。b)3-{4-[17-(3-羧基-1-甲基丙基)-3,7,12-三羟基-10,13-二甲基十六氢环戊二烯并[a]菲-3-基乙炔基]-3□-氟苯基}-2-甲基丙烯酸丁酯
将64mg氯化二(三苯基膦)钯(Ⅱ)、17mg CuI、0.5ml三乙胺和230mg 3-(4-溴-3-氟苯基)-2-甲基丙烯酸丁酯溶于10ml无水DMF中,用1小时滴加395mg 3□-乙炔基胆酸在10ml无水DMF中的溶液。将该混合物在60℃搅拌1小时,在60℃再缓慢地滴加395mg 3□-乙炔基胆酸在10ml无水DMF中的溶液。将该混合物在60℃再搅拌2小时,然后加入另外64mg氯化二(三苯基膦)钯(Ⅱ)和17mg CuI,将该混合物在60℃再搅拌2小时。最后再加入80mg 3□-乙炔基胆酸[lacuna],将该混合物在60℃搅拌2小时。将溶剂真空除去,把残余物置于100ml 5%硫酸氢钠水溶液中,将该混合物用EA萃取3次(每次100ml)。用硫酸钠干燥,将溶剂真空除去。通过硅胶色谱法纯化,用EA/MeOH5∶1洗脱,获得了90mg蜡状物。Rf(EA/MeOH 5∶1)=0.56 MS(FAB):667(M+H)+。c)4-{3-[2-氟-4-(3-胍基-2-甲基-3-氧代丙烯基)苯基乙炔基]-3,7,12-三羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸
将73mg盐酸胍和71mg叔丁醇钾溶于2ml无水DMF中,将该溶液在室温搅拌30分钟。把该悬浮液注射到85mg 3-{4-[17-(3-羧基-1-甲基丙基)-3,7,12-三羟基-10,13-二甲基十六氢环戊二烯并[a]菲-3-基乙炔基]-3-氟苯基}-2-甲基丙烯酸丁酯中,将该混合物在100℃搅拌5小时。冷却后,加入10ml水,用盐酸将该混合物的pH调节至4,用EA萃取3次(每次10ml)。用硫酸镁干燥,将溶剂真空除去。通过硅胶色谱法纯化,用丙酮/水10∶1洗脱,获得了15.5mg无定形固体。Rf(丙酮/水10∶1)=0.19 MS(ES):652(M+H)+。
实施例7:4-(3-{2-[2,6-二氟-4-(3-胍基-2-甲基-3-氧代丙烯基)苯基氨基]乙氧基}-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基)戊酸a)4-(7,12-二羟基-3-甲磺酰基氧基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基)戊酸
将100g胆酸溶于500ml吡啶中,在0℃经30分钟滴加23.1ml甲磺酰氯。将该混合物在室温搅拌3小时,然后在0℃倒入400ml硫酸在3升水内的溶液中,用EA提取4次(每次750ml)。用硫酸钠干燥,将溶剂真空除去。用二异丙基醚将该残余物结晶,获得了117.1g产物;熔点121℃(分解)。Rf(EA/HEP/乙酸5∶5∶1)=0.31 MS(FAB):487(M+H)+。b)4-[7,12-二羟基-3-(2-羟基乙氧基)-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸甲酯
将116g 4-(7,12-二羟基-3-甲磺酰基氧基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基)戊酸和130ml三乙胺溶于650ml乙二醇中,将该混合物在100℃搅拌3小时,在115℃搅拌7.5 小时。在0℃将该反应混合物倒入400ml硫酸在3升水内的溶液中,用EA提取7次(每次750ml)。用硫酸钠干燥,将溶剂真空除去。获得了INT中间体。
在0℃将130ml乙酰氯滴加到900ml甲醇中。然后加入INT在400ml[lacuna]中的溶液,将该混合物在室温搅拌6小时。将该混合物在室温放置60小时,然后倒入2.6升水中,并用二异丙基醚(DIP)提取8次(每次500ml)。然后用半饱和的碳酸氢钠水溶液将有机相洗涤6次(每次600ml)。将有机相用硫酸钠干燥,将溶剂真空除去。通过硅胶色谱法纯化,用EA洗脱,获得了32g树脂状固体。Rf(EA)=0.19 MS(FAB):467(M+H)+。c)4-{3-[2-(1,3-二氧代-1,3-二氢异吲哚-2-基)乙氧基]-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸甲酯
将1.5g 4-[7,12-二羟基-3-(2-羟基乙氧基)-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸甲酯、950mg三苯基膦和550mg邻苯二甲酰亚胺在26ml THF中加热至45℃,在该温度下滴加1.14ml偶氮二甲酸二乙酯。将该反应混合物在45℃搅拌2小时,然后倒入200ml半浓缩的碳酸氢钠水溶液中,用EA提取3次(每次200ml)。将有机相用硫酸钠干燥,将溶剂真空除去。通过硅胶色谱法纯化,用叔丁基甲基醚(MTB)洗脱,获得了1.76g粘稠的油状物。Rf(EA)=0.60 MS(FAB):602(M+Li)+。d)4-[3-(2-氨基乙氧基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸甲酯
将1.7g 4-{3-[2-(1,3-二氧代-1,3-二氢异吲哚-2-基)乙氧基]-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基}戊酸甲酯与0.52ml肼水合物(80%)溶于14ml甲醇中,并将该溶液回流3小时。然后冷却至40℃,用8.7ml 2N盐酸处理该反应混合物。将该混合物在40℃搅拌30分钟,然后将挥发性组分真空除去。通过硅胶色谱法纯化,用丙酮/水10∶1洗脱,获得了540mg树脂状固体。Rf(丙酮/水10∶1)=0.06 MS(FAB):466(M+H)+。e)4-[3-(2-氨基乙氧基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸
将3g 4-[3-(2-氨基乙氧基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸甲酯与310mgNaOH在5ml水和30ml甲醇中于室温搅拌24小时。将溶剂真空除去,把残余物置于200ml水中,并用盐酸将pH调节至7-7.5。将该混合物搅拌1小时,然后滤出产物。获得了1.6g浅黄色结晶固体。熔点185-195℃。Rf(CH2Cl2/MeOH/乙酸/水32∶8∶1∶1)=0.18 MS(ES):452(M+H)+。f)2-甲基-3-(3,4,5-三氟苯基)丙烯酸乙酯
将4.3ml 2-膦酰基丙酸三乙酯溶于30ml无水THF中,在0℃滴加12.5ml 1.6 N正丁基锂在己烷中的溶液。将该混合物在室温搅拌15分钟,然后滴加3.2g 3,4,5-三氟苯甲醛在8ml无水THF中的溶液。将该混合物在室温搅拌1小时,然后在室温放置16小时。用300ml水稀释该反应混合物,加入30ml饱和碳酸钠水溶液,并用EA提取3次(每次100ml)。用硫酸钠干燥,将溶剂真空除去。通过硅胶色谱法纯化,用EA/HEP 1∶8洗脱,获得了3.8g无色结晶;熔点54℃。Rf(EA/HEP 1∶8)=0.35 MS(DCl):245(M+H)+。g)3-(4-{2-[17-(3-羧基-1-甲基丙基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-3-基氧基]乙基氨基}-3,5-二氟苯基)-2-甲基丙烯酸乙酯
将600mg 4-[3-(2-氨基乙氧基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基]戊酸、390mg 2-甲基-3-(3,4,5-三氟苯基)丙烯酸乙酯和828mg碳酸钾在10ml二甲基乙酰胺中于130℃搅拌2.5小时。冷却后,用400ml二氯甲烷将该反应混合物稀释,并用400ml 5%硫酸氢钠水溶液洗涤。用硫酸镁干燥,将溶剂真空除去。通过硅胶色谱法纯化,用CH2Cl2/MeOH 10∶1洗脱,获得了155mg无色油状物。Rf(CH2Cl2/MeOH 10∶1)=0.27 MS(ES):676(M+H)+。i)4-(3-{2-[2,6-二氟-4-(3-胍基-2-甲基-3-氧代丙烯基)苯基氨基]乙氧基}-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-17-基)戊酸
将130mg盐酸胍和125mg叔丁醇钾在1ml无水DMF中于室温搅拌30分钟。然后加入150mg 3-(4-{2-[17-(3-羧基-1-甲基丙基)-7,12-二羟基-10,13-二甲基十六氢环戊二烯并[a]菲-3-基氧基]乙基氨基}-3,5-二氟苯基)-2-甲基丙烯酸乙酯在1ml无水DMF中的溶液,并在110-115℃搅拌6小时。然后,将该反应混合物倒入100ml水中,用盐酸调节pH至6,并过滤出产物。将产物在高真空下干燥,获得了8.0mg无定形固体。Rf(CH2Cl2/MeOH/乙酸/水32∶8∶1∶1)=0.21 MS(ES):689(M+H)+。
Claims (10)
R(A)、R(B)、R(C)、R(D)彼此独立地为氢、F、Cl、Br、I、CN、OH、NH2、-(C1-C8)-烷基、-O-(C1-C8)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为(C3-C8)-环烷基、苯基、苄基、NHR(7)、NR(7)R(8)、O-(C3-C6)-链烯基、O-(C3-C8)-环烷基、O-苯基、O-苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;
R(7)、R(8)彼此独立地为氢、-(C1-C8)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为(C3-C8)-环烷基、(C3-C6)-链烯基、(C3-C8)-环烷基、苯基、苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;或者
R(7)、R(8)一起形成具有4或5个亚甲基的链,其中的一个CH2基团可被氧、硫、NH、N-CH3或N-苄基替代;
R(9)、R(10)彼此独立地为氢、-(C1-C4)-烷基、(C1-C4)-全氟烷基;
x是0、1或2;
y是0、1或2;
R(E)、R(F)彼此独立地为氢、F、Cl、Br、I、CN、(C1-C8)-烷基、O-(C1-C8)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为(C3-C8)-环烷基、O-(C3-C6)-链烯基、O-(C3-C8)-环烷基、O-苯基、O-苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;
R(1)、R(2)、R(3)彼此独立地为氢、F、Cl、Br、I、CN、-(C1-C8)-烷基、-O-(C1-C8)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为-(C=O)-N=C(NH2)2、-(SO0-2)-(C1-C8)-烷基、-(SO2)-NR(7)R(8)、-O-(C0-C8)-亚烷基苯基、-(C0-C8)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、-(C0-C8)-亚烷基-NR(9)R(10)取代最高达3次;
L是-O-、-NR(47)-、-(C1-C8)-亚烷基-、-(C1-C8)-亚链烯基-、-(C1-C8)-亚炔基-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-O-CO-(CH2)n-O-、-SO2-NR(48)-(CH2)n-O-、-NR(48)-CO-CH2-CH2-CO-NR(48)-(CH2)n-O-、-NR(48)-CO-CH=CH-CO-NR(48)-(CH2)n-O-、-NR(48)-SO2-(CH2)n-O-;
R(47)是氢、(C1-C8)-烷基、R(48)-CO-、苯基、苄基;
R(48)是氢、(C1-C8)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
n是1-8;
R(40)-R(45)彼此独立地为氢、-OR(50)、-SR(50)、NHR(50)、-NR(50)2、-O-(CO)-R(50)、-S-(CO)-R(50)、-NH-(CO)-R(50)、-O-PO-(OR(50))-OR(50)、-O-(SO2)-OR(50)、-R(50)、L上的键;或者
每种情况下的R(40)与R(41)、R(42)与R(43)、R(44)与R(45)一起形成羰基的氧;
其中R(40)-R(45)当中总是恰好有一个基团是L上的键;
K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-HN-CH2-COOH、-N(CH3)CH2CO2H、-HN-CH(R46)CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子;
R(46)是氢、C1-C4-烷基、苄基、-CH2-OH、H3CSCH2CH2-、HO2CCH2-、HO2CCH2CH2-;
R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次。
2.权利要求1的式Ⅰ化合物或其可药用盐和生理功能衍生物,其中
T1和T2彼此独立地为或氢,其中T1和T2不能同时为氢;L-z是
R(E)是氢、F、Cl、CN、(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次,或者R(E)为(C3-C6)-环烷基、(C3-C8)-链烯基、O-(C3-C6)-环烷基、O-苯基、O-苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基、NR(9)R(10)取代最高达3次;
R(9)、R(10)彼此独立地为氢、CH3、CF3;
R(1)、R(2)、R(3)彼此独立地为氢、F、Cl、CN、-SO2-(C1-C4)-烷基、-SO2-N((C1-C4)-烷基)2、-SO2-NH(C1-C4)-烷基、-SO2-NH2、-SO2-(C1-C4)-烷基、-(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为-O-(C0-C4)-亚烷基苯基、-(C0-C4)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
L是-O-、-NR(47)-、-(C1-C4)-亚烷基-、-(C1-C4)-亚链烯基-、-(C1-C4)-亚炔基-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-SO2-NR(48)-(CH2)n-O-;
R(47)是氢、(C1-C4)-烷基、R(48)-CO-、苯基、苄基;
R(48)是氢、(C1-C4)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
n是1-4;
R(41)、R(42)、R(45)彼此独立地为氢、-OR(50)、NHR(50)、-NR(50)2、-O-(CO)-R(50)、-NH-(CO)-R(50);
R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-HN-CH2-COOH、-N(CH3)CH2CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子。
3.权利要求1或2的式Ⅰ化合物或其可药用盐,其中
R(E)是氢、F、Cl、CN、(C1-C4)-烷基、(C1-C4)-烷基、-O(C1-C4)-烷基、CF3、-OCF3;
R(1)、R(2)彼此独立地为氢、F、Cl、CN、-SO2-CH3、-(C1-C4)-烷基、-O-(C1-C4)-烷基,其中所述烷基可被F取代一次或多次,或者彼此独立地为-O-(C0-C4)-亚烷基苯基、-(C0-C4)-亚烷基苯基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
R(3)是氢;
L是-O-、-NR(47)-、-CH2-CH2-、-CH=CH-、-(C≡C)-、-COO-、-CO-NR(47)-、-SO2-NR(47)-、-O-(CH2)n-O-、-NR(47)-(CH2)n-O-、-NR(48)-CO-(CH2)n-O-、-CO-NR(48)-(CH2)n-O-、-SO 2 -NR(48)-(CH2)n-O-;
R(47)是氢、(C1-C4)-烷基、R(48)-CO-、苯基、苄基;
R(48)是氢、(C1-C4)-烷基、苯基和苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次;
n是1-4;
R(41)是氢、-OH;
K是-OR(50)、-NHR(50)、-NR(50)2、-HN-CH2-CH2-CO2H、-HN-CH2-CH2-SO3H、-HN-CH2-COOH、-N(CH3)CH2CO2H、-OKa,其中Ka是阳离子,例如碱金属或碱土金属离子或季铵离子;
R(50)是氢、(C1-C4)-烷基、苯基或苄基,其中所述苯核可被F、Cl、CF3、甲基、甲氧基取代最高达3次。
5.包含一种或多种如权利要求1-4中一项或多项所述的化合物的药物。
6.包含一种或多种如权利要求1-4中一项或多项所述的化合物和一种或多种降脂活性化合物的药物。
7.用作预防或治疗胆结石的药物的权利要求1-4中一项或多项的化合物。
8.用作治疗胆结石的药物的与至少一种另外的降脂活性化合物联合使用的权利要求1-4中一项或多项的化合物。
9.制备包含一种或多种如权利要求1-4中一项或多项所述的化合物的药物的方法,包括将所述活性化合物与药学上合适的赋形剂混合,并将该混合物制成适于给药的剂型。
10.权利要求1-4中一项或多项的化合物在制备用于预防或治疗胆结石的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19849722A DE19849722A1 (de) | 1998-10-28 | 1998-10-28 | Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
DE19849722.9 | 1998-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1325403A true CN1325403A (zh) | 2001-12-05 |
Family
ID=7885948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99812751A Pending CN1325403A (zh) | 1998-10-28 | 1999-10-15 | 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6166002A (zh) |
EP (1) | EP1124841B1 (zh) |
JP (1) | JP4616479B2 (zh) |
KR (1) | KR20010085973A (zh) |
CN (1) | CN1325403A (zh) |
AT (1) | ATE236191T1 (zh) |
AU (1) | AU757365B2 (zh) |
BR (1) | BR9914929A (zh) |
CA (1) | CA2349523A1 (zh) |
CZ (1) | CZ20011429A3 (zh) |
DE (2) | DE19849722A1 (zh) |
DK (1) | DK1124841T3 (zh) |
ES (1) | ES2191466T3 (zh) |
HK (1) | HK1041271A1 (zh) |
HU (1) | HUP0103751A3 (zh) |
ID (1) | ID29025A (zh) |
PL (1) | PL348108A1 (zh) |
PT (1) | PT1124841E (zh) |
RU (1) | RU2232769C2 (zh) |
TR (1) | TR200101163T2 (zh) |
WO (1) | WO2000024761A1 (zh) |
ZA (1) | ZA200103106B (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19941764A1 (de) | 1999-09-02 | 2001-03-15 | Aventis Pharma Gmbh | Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente |
EP1646371A4 (en) | 2003-06-26 | 2010-09-22 | Biotron Ltd | ANTIVIRAL COMPOSITIONS AND METHODS |
DE10338554A1 (de) * | 2003-08-22 | 2005-03-31 | Aventis Pharma Deutschland Gmbh | Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US7390837B2 (en) | 2004-01-30 | 2008-06-24 | Ethicon, Inc. | Germicidal compositions containing phenylmalonaldehyde-type compounds, or mixtures of phenylmalonaldehyde-type compounds and phthalaldehydes, and methods of using such compositions for disinfection or sterilization |
US6891069B1 (en) | 2004-01-30 | 2005-05-10 | Ethicon, Inc. | Synthesis of 4-substituted phthalaldehyde |
US7476767B2 (en) | 2004-01-30 | 2009-01-13 | Ethicon, Inc. | Alpha-hydroxy sulfonate aldehydes, germicidal compositions containing the alpha-hydroxy sulfonate aldehydes, or mixtures of alpha-hydroxy sulfonate aldehydes and phthalaldehydes, and methods of using the compounds or compositions for disinfection or sterilization |
US7291649B2 (en) | 2005-06-29 | 2007-11-06 | Ethicon, Inc. | Forming germicidal aromatic dialdehydes with acetals |
CZ301037B6 (cs) * | 2007-09-06 | 2009-10-21 | Vysoká škola chemicko-technologická v Praze | Amidové konjugáty steroidních a žlucových kyselin s D-glukosaminem a zpusob jejich prípravy |
WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
KR20230132619A (ko) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW289021B (zh) * | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
JPH0959162A (ja) * | 1995-08-28 | 1997-03-04 | Makoto Takahashi | 胆石溶解剤 |
DE19633966A1 (de) * | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
1998
- 1998-10-28 DE DE19849722A patent/DE19849722A1/de not_active Withdrawn
-
1999
- 1999-10-15 ES ES99949001T patent/ES2191466T3/es not_active Expired - Lifetime
- 1999-10-15 AU AU62032/99A patent/AU757365B2/en not_active Ceased
- 1999-10-15 CN CN99812751A patent/CN1325403A/zh active Pending
- 1999-10-15 PT PT99949001T patent/PT1124841E/pt unknown
- 1999-10-15 RU RU2001114207/04A patent/RU2232769C2/ru not_active IP Right Cessation
- 1999-10-15 EP EP99949001A patent/EP1124841B1/de not_active Expired - Lifetime
- 1999-10-15 JP JP2000578331A patent/JP4616479B2/ja not_active Expired - Fee Related
- 1999-10-15 DE DE59904875T patent/DE59904875D1/de not_active Expired - Lifetime
- 1999-10-15 AT AT99949001T patent/ATE236191T1/de not_active IP Right Cessation
- 1999-10-15 CA CA002349523A patent/CA2349523A1/en not_active Abandoned
- 1999-10-15 ID IDW00200100935A patent/ID29025A/id unknown
- 1999-10-15 BR BR9914929-0A patent/BR9914929A/pt not_active IP Right Cessation
- 1999-10-15 PL PL99348108A patent/PL348108A1/xx unknown
- 1999-10-15 CZ CZ20011429A patent/CZ20011429A3/cs unknown
- 1999-10-15 WO PCT/EP1999/007828 patent/WO2000024761A1/de not_active Application Discontinuation
- 1999-10-15 TR TR2001/01163T patent/TR200101163T2/xx unknown
- 1999-10-15 KR KR1020017005343A patent/KR20010085973A/ko active IP Right Grant
- 1999-10-15 DK DK99949001T patent/DK1124841T3/da active
- 1999-10-15 HU HU0103751A patent/HUP0103751A3/hu unknown
- 1999-10-20 US US09/422,146 patent/US6166002A/en not_active Expired - Lifetime
-
2001
- 2001-04-17 ZA ZA200103106A patent/ZA200103106B/xx unknown
-
2002
- 2002-04-15 HK HK02102812.0A patent/HK1041271A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TR200101163T2 (tr) | 2001-08-21 |
HUP0103751A3 (en) | 2002-12-28 |
RU2232769C2 (ru) | 2004-07-20 |
CZ20011429A3 (cs) | 2001-08-15 |
PL348108A1 (en) | 2002-05-06 |
US6166002A (en) | 2000-12-26 |
PT1124841E (pt) | 2003-08-29 |
AU757365B2 (en) | 2003-02-20 |
AU6203299A (en) | 2000-05-15 |
ZA200103106B (en) | 2002-08-28 |
ES2191466T3 (es) | 2003-09-01 |
DE19849722A1 (de) | 2000-05-04 |
HK1041271A1 (zh) | 2002-07-05 |
ID29025A (id) | 2001-07-26 |
JP4616479B2 (ja) | 2011-01-19 |
DK1124841T3 (da) | 2003-07-28 |
JP2002528460A (ja) | 2002-09-03 |
ATE236191T1 (de) | 2003-04-15 |
DE59904875D1 (de) | 2003-05-08 |
KR20010085973A (ko) | 2001-09-07 |
EP1124841A1 (de) | 2001-08-22 |
HUP0103751A2 (hu) | 2002-04-29 |
WO2000024761A1 (de) | 2000-05-04 |
BR9914929A (pt) | 2001-07-10 |
CA2349523A1 (en) | 2000-05-04 |
EP1124841B1 (de) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1325403A (zh) | 胆汁酸取代的苯基链烯酰基胍、其制备方法、其作为药物或诊断剂的应用以及含有它们的药物 | |
CA2369070C (en) | 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof | |
CN1042539C (zh) | 11,21-二苯基-19-去甲孕甾烷衍生物 | |
CZ206299A3 (cs) | Způsob přípravy enantiomerně obohaceného THREO-metalfenidátu | |
KR20020046948A (ko) | 에폭사이드 결정의 제조방법 | |
CN1321149A (zh) | 托拉沙得新晶体变型ⅲ | |
CN1200939C (zh) | 新的四氢吡啶,它们的制备方法以及含有它们的药物组合物 | |
RU2247125C2 (ru) | Конъюгаты 4-бензиламинохинолинов с желчной кислотой и их гетероаналоги, способ их получения и лекарственные средства на основе этих соединений | |
JPS59139400A (ja) | 抗アルドステロン活性ステロイド誘導体 | |
JP4768941B2 (ja) | 胆汁酸置換フェニルアルケノイルグアニジン、それらの製造方法、医薬または診断薬としてのそれらの使用、およびそれらを含む医薬 | |
JP5987102B1 (ja) | トリアリールメタン組成物,眼膜染色のための染色組成物 | |
EP0401262B1 (en) | 24r-scymnol, and preparation and use thereof | |
CA1141372A (en) | Synthesis of steroids | |
CN107722043B (zh) | 一种手性胺基化合物及其中间体的制备方法 | |
CN102036950A (zh) | 制备3-(2,2,2-三甲基肼)丙酸盐二水合物的新方法 | |
JPH07316173A (ja) | リン酸ジエステルのモノカリウム塩結晶の製造方法 | |
DE19945385A1 (de) | Substituierte 4-Benzylaminochinoline und ihre Heteroanlagen, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung | |
DE10028193A1 (de) | Substituierte 4-Benzylamminochinoline und ihre Heteroanalogen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika, sowie sie enthaltende Medikamente | |
CN108659090A (zh) | 一种17β-硫代羧酸氯甲酯类甾体化合物的制备方法 | |
MXPA01004147A (en) | Bile-acid substituted phenyl alkenoyl guanidines, method for the production thereof, use thereof as medicaments or diagnostic agents and medicaments that contain them | |
WO2012101648A1 (en) | Novel process for the synthesis of enantiomerically pure 2-methoxy-5-[(2r)-2-(4-alkylpiperazin-l-yl)propyl]-benzenesulfonamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C10 | Entry into substantive examination | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1041271 Country of ref document: HK |
|
AD01 | Patent right deemed abandoned | ||
C20 | Patent right or utility model deemed to be abandoned or is abandoned |